Milestone Pharmaceuticals Inc (MIST)

Jan 7, 2025, 8:00 AM EST - 10 days ago

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 12, 2024, 9:03 AM EST - 2 months ago

Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Sep 6, 2024, 7:00 AM EDT - 4 months ago

Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China

Sep 4, 2024, 8:00 AM EDT - 4 months ago

Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

Aug 8, 2024, 4:17 PM EDT - 5 months ago

Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Jun 12, 2024, 8:00 AM EDT - 7 months ago

Milestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024

May 31, 2024, 8:00 AM EDT - 8 months ago

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

May 29, 2024, 7:00 AM EDT - 8 months ago

Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™

May 13, 2024, 7:15 AM EDT - 8 months ago

Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

Apr 17, 2024, 8:00 AM EDT - 9 months ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium

Apr 8, 2024, 11:36 AM EDT - 10 months ago

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

Apr 1, 2024, 8:00 AM EDT - 10 months ago

Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

Mar 21, 2024, 7:14 AM EDT - 10 months ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

Feb 29, 2024, 4:01 PM EST - 11 months ago

Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference

Feb 29, 2024, 7:00 AM EST - 11 months ago

Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants

Feb 28, 2024, 4:37 PM EST - 11 months ago

Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants

Jan 2, 2024, 7:06 AM EST - 1 year ago

Top 5 Health Care Stocks That Could Lead To Your Biggest Gains in January - Corcept Therapeutics (NASDAQ:CORT), Kintara Therapeutics (NASDAQ:KTRA)

CORT RPID

Dec 26, 2023, 7:00 AM EST - 1 year ago

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Nov 21, 2023, 7:00 AM EST - 1 year ago

Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 13, 2023, 6:57 AM EST - 1 year ago

Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

Nov 11, 2023, 10:00 AM EST - 1 year ago

Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023

Nov 7, 2023, 7:00 AM EST - 1 year ago

Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR

Oct 24, 2023, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Sep 27, 2023, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023

Sep 5, 2023, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 10, 2023, 7:35 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update

Jun 20, 2023, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet

Jun 1, 2023, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference

May 22, 2023, 2:37 PM EDT - 1 year ago

Milestone Pharmaceuticals: Worthy Of A Dart Throw

May 22, 2023, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate

May 11, 2023, 7:16 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update

May 8, 2023, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate

Apr 12, 2023, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

Mar 29, 2023, 9:17 AM EDT - 1 year ago

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update

Mar 28, 2023, 7:00 AM EDT - 1 year ago

Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT

Mar 6, 2023, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia

Feb 28, 2023, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals to Present at Upcoming Investor Conferences

Nov 29, 2022, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT

Nov 22, 2022, 7:00 AM EST - 2 years ago

Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 10, 2022, 7:21 AM EST - 2 years ago

Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update

Nov 7, 2022, 12:13 PM EST - 2 years ago

Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022

Nov 5, 2022, 2:28 AM EDT - 2 years ago

Milestone Pharmaceuticals: Potential NDA Submission Of Etripamil Catalyst Set For Mid-2023

Oct 30, 2022, 7:25 AM EDT - 2 years ago

Milestone Pharmaceuticals: Looking Attractive After Drop On Positive News

Oct 25, 2022, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022

Oct 17, 2022, 9:14 AM EDT - 2 years ago

Milestone's stock jumps 25% on positive data for tachycardia treatment

Oct 17, 2022, 6:00 AM EDT - 2 years ago

Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia

Sep 6, 2022, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 10, 2022, 4:15 PM EDT - 2 years ago

Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update

May 17, 2022, 7:00 AM EDT - 2 years ago

Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference